Published in final edited form as:

J Rheumatol. 2014 March ; 41(3): 599–612. doi:10.3899/jrheum.131249.

Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review

Gulen Hatemi, MD [Associate Professor],

Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey

Peter A. Merkel, MD, MPH [Professor of Medicine and Epidemiology],

Division of Rheumatology and Department of Epidemiology, University of Pennsylvania, Philadelphia, PA, USA

Vedat Hamuryudan, MD [Professor of Rheumatology],

Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey

Maarten Boers, MD, MSc, PhD [Professor of Clinical Epidemiology],

Department of Clinical Epidemiology, VU University Medical Center, Amsterdam, The Netherlands

Haner Direskeneli, MD [Professor of Rheumatology],

Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey

Sibel Z. Aydin, MD [Associate Professor], and

Department of Rheumatology, Istanbul Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey

Hasan Yazici, MD [Professor of Rheumatology]

Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey.

Abstract

Behçet syndrome (BS) is a multisystem vasculitis that is most active during young adulthood, causing serious disability and significant impairment in quality of life. Differences in the disease course, severity, and organ involvement between patients, depending on the age at presentation and sex, makes it impossible to determine a single management strategy. The diversity and variability in the outcome measures used in clinical trials in BS makes it difficult to compare the results or inform physicians about the best management strategy for individual patients. There is a large unmet need to determine or develop validated outcome measures for use in clinical trials in BS that are acceptable to researchers and regulatory agencies. We conducted a systematic review to describe the outcomes and outcome measures that have been used in clinical trials in BS. This review revealed the diversity and variability in the outcomes and outcome measures and the lack of standard definitions for most outcomes and rarity of validated outcome tools for disease

assessment in BS. This systematic literature review will identify domains and candidate instruments for use in a Delphi exercise, the next step in the development of a core set of outcome measures that are properly validated and widely accepted by the collaboration of researchers from many different regions of the world and from different specialties, including rheumatology, ophthalmology, dermatology, gastroenterology, and neurology.

Keywords

BEHÇET SYNDROME; OUTCOMES; ASSESSMENT; SYSTEMATIC REVIEW

Behçet syndrome (BS) is a multisystem vasculitis that affects both men and women during young adulthood with significant effects on quality of life (QOL); it can result in serious disability and premature death. Manifestations include mucocutaneous lesions such as oral ulcers, genital ulcers, papulopustular and nodular lesions, joint involvement (usually in the form of a self-limited monoarthritis or arthralgia), eye involvement typically manifesting as panuveitis that may lead to blindness if left untreated, vascular involvement causing arterial aneurysms that may be lethal, deep venous thrombi, neurologic involvement that can cause permanent disability, and gastrointestinal (GI) involvement that is often indistinguishable from inflammatory bowel disease. Given its pathophysiology and spectrum of manifestations, BS is best classified as a form of vasculitis. There are many reasons to call it a syndrome rather than a disease, in particular the considerable variation in disease presentation depending on demography and geography¹.

The disease course, severity, and types of organ involvement vary substantially among patients depending on their age and sex and the age of onset. Thus, it is impossible to determine a single management strategy². Several clinical trials have been conducted in patients with BS, addressing different types of organ involvement such as mucocutaneous or ocular disease³. However, most of the outcome measures used in these trials were neither validated nor widely accepted, leading investigators to add to the clutter by creating their own definitions of activity, severity, or response. The diversity and variability in the outcome measures used in trials of BS make it difficult to compare trial results, combine findings into metaanalyses, or guide physicians on management strategies.

The development of new biologic agents with immunomodulatory actions has increased the interest of both doctors and the pharmaceutical companies in conducting clinical trials in BS. However, the lack of uniform, widely accepted outcome measures is an obstacle to designing randomized controlled trials (RCT) that meet regulatory agencies' expectations. This in turn reduces the enthusiasm of industry support for such research. OMERACT has guided the development of data-driven outcome measures in several diseases. The OMERACT Vasculitis Working Group has developed a core set of outcome measures for use in clinical trials of antineutrophil cytoplasmic antibody-associated vasculitis and is continuing work on outcome measures for large-vessel vasculitis^{4,5}. The Working Group is pursuing a similar approach, within the OMERACT framework, to develop validated outcome measures for clinical trials in BS.

As a first step in the development of a core set for BS, the aim of this systematic review is to describe the strengths and shortcomings of the outcomes and outcome measures that have been used in RCT, uncontrolled interventional studies, observational studies, longitudinal cohorts, case control studies, and biomarker and genetic association studies in BS.

METHODS

A systematic literature search was performed to identify all published articles that included defined outcome measures or outcomes in BS. PubMed was searched for articles published between January 1946 and November 2012. To avoid missing any relevant articles, no limits were used during the literature search, and titles and abstracts of all articles retrieved by the keywords “Behcet's syndrome OR Behcet's disease OR Adamantiades Behcet OR Behcet*” were evaluated for inclusion criteria.

Publications reviewed included all RCT, uncontrolled observational or retrospective interventional studies, longitudinal or retrospective cohort studies, case-control studies, biomarker studies, or genetic association studies reporting on at least 20 patients with BS and including at least 1 outcome or outcome measure. Original articles involving humans, published in English, German, French, or Turkish were included. A hand search of references of selected articles for identifying relevant studies was also performed. Unpublished reports, congress proceedings, or abstracts were excluded.

From the selected articles, data were extracted regarding the outcome measures and outcomes used in interventional studies and cohorts, as well as definitions of activity and severity used in biomarker and genetic association studies and case control studies. The outcomes and outcome measures were analyzed in 3 groups based on study type: (1) randomized controlled studies; (2) biomarker and genetic association studies; and (3) all other studies.

We also evaluated the outcomes and outcome measures in terms of their appropriateness to the OMERACT 2.0 Filter. We identified outcomes that addressed at least 1 of the 4 core areas incorporated into Filter 2.0: “death”, “life impact”, “pathophysiological manifestations”, and “resource use/economical impact area.”⁶

Quality assessment of the articles was not done because the aim of the exercise was to determine all outcomes and outcome measures used in trials of BS regardless of the methodological quality.

RESULTS

Figure 1 shows the flowchart of the systematic review results. In the first phase of the review, 8286 articles were identified. The following types of articles were excluded: informative reviews; case reports and other studies reporting on fewer than 20 patients; trials in languages other than English, French, German, or Turkish; clinical trials not reporting any outcomes such as epidemiological studies on the prevalence and types of involvement of BS in a country; trials not related to BS or where the primary area of interest was not BS such as general uveitis trials; and animal studies. Basic science studies including genetic association

studies were excluded after reading the title and abstract. The full text of the remaining 259 articles were retrieved. Among these, 249 articles were ultimately determined to meet the full set of inclusion criteria. Tables 1–3 show the outcome measures used in these trials⁷⁻²⁵⁶.

Outcome measures for overall disease assessment

The outcomes and outcome measures that are used for the overall evaluation of BS without organ-specific endpoints are given in Table 1. The most commonly used measure for evaluating disease activity was the Behçet's Disease Current Activity Form, which was used in 24/248 (9.6%) of the published studies⁷⁻³⁰. There are 4 other activity measures that were used in a few trials each^{18,20,31-37}. Several researchers used their own definition of activity³⁸⁻⁸⁷. The definitions of activity varied from requiring a minimum of 1 to 3 manifestations, including oral ulcers, genital ulcers, skin lesions, uveitis, vascular lesions, or neurologic lesions. Some studies did not provide an explanation of how active patients were defined^{88,89,90,91}. Mortality is rarely used as a primary or even secondary endpoint of interest in studies of BS⁹²⁻¹⁰³.

For evaluating disease severity, the most commonly used index was the Krause Total Severity Score. This was used in 15/248 (6.0%) of published studies^{38,46,51,57,104-114}. Several researchers used their own definition of disease severity^{12,32,60,65,82,115,116,117}. Similarly, many studies incorporated outcomes unique to that study for definitions of relapse, response (complete/partial), and remission (complete/partial)^{30,71,72,90,118,119,120,121,122,123}.

There was 1 validated health-related QOL measure specific for BS: the Behçet Disease Quality of Life. This measure has been used in only a few clinical trials^{19,124,125}.

Organ-specific outcomes and outcome measures

Organ-specific outcomes and outcome measures used in trials are summarized in Table 2. The only organ-specific outcome measure that was developed for mucocutaneous BS and validated was the oral ulcer composite index¹²⁶. The frequency, duration, size, pain, severity, and healing time of each of the mucocutaneous lesions were used as outcomes in different combinations in several studies^{57,118,120,127-135,138-140,185,243-251}. Similarly, the number, frequency, severity, duration, and pain of arthritis episodes were reported in several studies^{132,133,137,139,141,142,143}.

Organ-specific outcome measures used in trials for eye involvement are given in Table 2. Visual acuity^{9,15,16,120,144-196,252-254} and inflammatory attacks^{9,15,120,144,147,155-158,161,162,164,165,166,169,170,171,173,176,181,183,184,186,188-196} are the most widely used outcome measures. However, the definition of an inflammatory flare varied widely among studies, and visual acuity was reported in several different ways, including change on Snellen chart or Japanese standard Landolt visual acuity chart, calculating the LogMar (logarithm of the minimum angle of resolution), or the percentage of patients who had a certain level of improvement. Loss of useful vision is another similar outcome used^{99,160,163,167,174,175,176,177}. Different components of the Standardization of Uveitis Nomenclature Working Group Criteria, a generic uveitis measure, were used in some of the trials for BS^{14-16,146,150,154,176}. The Ben Ezra Disease

Activity Index, specifically developed for evaluating uveitis in BS, was also used in a few studies^{15,25,152,153}.

Outcomes and outcome measures used in trials for vascular^{92,93,94,95,96,100,102,197-203}, neurologic^{97,204-210}, and GI involvement²¹¹⁻²²⁷ are given in Table 2. There were no RCT or prospective interventional trials for vascular involvement of BS. Studies that report on longterm followup of patients with BS with vascular involvement or retrospective reviews of surgical outcomes usually reported relapses/recurrences, remission, operation and reoperation rates and postoperative complications^{92,93,94,95,96,100,102,197-203}. Relapses/recurrences were defined as a new lesion or a progression of an already present lesion. Remission was defined as the absence of a new or progressing lesion.

There were also no RCT for neurologic or GI involvement of BS. There is 1 GI index that was developed and validated specifically for BS (Disease Activity Index for Intestinal Behçet Disease)^{211,216,218,220,221}. This index showed a higher correlation with physician global assessment and higher responsiveness than the Crohn Disease Activity Index. Many studies used indexes and outcomes developed for inflammatory bowel diseases^{211,224,227}.

Laboratory outcome measures

Erythrocyte sedimentation rate^{9,16,22,24,34,40,43,47,49,59,60,61,63,66,67,68,69,76,77,85,89,94,139,143,177,220,228} and C-reactive protein^{9,16,24,40,43,47,49,59,60,66,67,76,77,85,89,94,143,177,216,220,228} levels were used as indicators of disease activity. No laboratory measure has been validated as a biomarker of disease activity in BS.

Generic measures

Several generic measures were used to evaluate the QOL and psychological, cognitive, or sexual effect of BS (Table 3)^{10,17,19,23,46,57,60,124,125,128,141,151,207,208,228-241,255,256}. Among these, only the oral health-related QOL was specifically validated for BS¹²⁸. The most frequently used psychological indexes were the Beck Depression Index^{17,60,141,208,230,232,235,236,238,239,240} and Beck Anxiety Scale^{230,238,239,241}.

Evaluation of the outcomes that were reviewed according to the OMERACT 2.0 Filter

Death, which is one of the core areas in the Filter 2.0, was included as an outcome in 12 trials⁹²⁻¹⁰³. None of the RCT reported death. Life impact was addressed by 1 BS specific measure, Behçet Disease Quality of Life^{19,124,125}, and several generic measures given in Table 3^{10,17,19,23,46,57,60,124,125,128,141,151,207,208,228-241,255,256}. There was 1 cost analysis study in BS that retrospectively analyzed direct costs such as medication, diagnostic tests, hospital visits, hospitalization fees, and lodging and transportation expenses and indirect costs such as lost workdays and wages by questioning the patients²⁴². However, none of the interventional trials included an instrument to address the “resource use/economical impact area.” The rest of the outcomes given in Table 1 and 2 are related to the “patho-physiological manifestations” area.

DISCUSSION

This systematic review revealed the diversity and variability in the outcomes and outcome measures used in clinical research in BS. It shows that there are no standard definitions for most outcomes and few validated outcome tools for any aspect of disease assessment in BS. The number of different outcomes assessed and the inconsistency in assessment methods is problematic. For example, visual acuity was used in 51 of the 63 trials studying eye disease in BS, but 5 different assessment methods were used among the 51 trials, making comparison of trial results extremely difficult.

There are 5 activity scales, 1 severity scale, a composite index for oral ulcers, and a QOL scale that were developed for BS. However, these measures have not been widely adopted for use by clinical researchers. Many investigators have preferred to use their own definitions of activity³⁸⁻⁸⁷ or severity^{12,32,60,65,82,115,116,117}, or have included “generic” measures such as the Medical Outcomes Study Short Form-36 in their trials^{46,57,151,239}. Similarly, some authors studying specific physiologic manifestations of BS have used outcome tools developed for other diseases, for example, uveitis scales or measures of inflammatory bowel disease; however, these tools have not been validated for BS. It may be appropriate to adapt existing tools for use in BS, but such use should be supported by properly conducted data analyses. Regarding the disease specific scores, they are composite scores of each item such as oral ulcers, genital ulcers, skin lesions, and eye lesions, and were not developed with the purpose of evaluating the individual items separately; however, it would be interesting to study the performance of each item outside composite scores and compare them to the organ-specific outcome measures.

During the OMERACT 11 meeting, the new Filter 2.0 was introduced. The Filter 2.0 approach suggests that all core sets of outcome measures should include at least 1 instrument from the 3 core areas of “death”, “life impact”, and “pathophysiological manifestations”, and preferably 1 outcome measure addressing “resource use/economical impact area.” Thus, we evaluated the outcomes and outcome measures used in BS trials in terms of their relevance to these core areas. None of the RCT reported death. It can be assumed that there were no deaths since it was not mentioned among the adverse events; however, death was not formally reported in any of the trials. Similarly “resource use/economical impact area” was not covered in any of the interventional trials. The outcomes and outcome measures used were mostly related to the “life impact” and “pathophysiological manifestations” areas. Work on the development of a core set of outcomes for BS should strive to address each of the core areas of Filter 2.0.

Part of the evolving research agenda for the OMERACT Vasculitis Working Group is to work toward developing a core set of outcomes in BS. Among the next steps in this process is to conduct a Delphi exercise among international investigators and clinical experts in BS to reach consensus on outcomes of interest in BS. Apart from determining the current status of outcomes research in BS, the data derived from this systematic literature review will be used as a starting point to identify the domains and candidate instruments for use in the Delphi exercise. The collaboration of investigators from many different regions of the world and from different medical specialties, including rheumatology, ophthalmology,

dermatology, gastroenterology, and neurology will be needed to develop a core set of outcome measures that are properly tested, well validated, and broadly acceptable for use in randomized trials in BS.

Acknowledgments

Supported by the Vasculitis Clinical Research Consortium (www.RareDiseasesNetwork.org/vcrc) through the US National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54AR057319), the National Center for Research Resources (U54 RR01949703), the Office of Rare Diseases Research/National Center for Advancing Translational Sciences, and the Patient-Centered Outcomes Research Institute.

REFERENCES

1. Yazici H, Ugurlu S, Seyahi E. Behcet syndrome: is it one condition? Clin Rev Allergy Immunol. 2012; 43:275–80. [PubMed: 22674015]
2. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008; 67:1656–62. [PubMed: 18245110]
3. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis. 2009; 68:1528–34. [PubMed: 18420940]
4. Direskeneli H, Aydin SZ, Kermani TA, Matteson EL, Boers M, Herlyn K, et al. Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol. 2011; 38:1471–9. [PubMed: 21724719]
5. Merkel PA, Aydin SZ, Boers M, Direskeneli H, Herlyn K, Seo P, et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol. 2011; 38:1480–6. [PubMed: 21724720]
6. Boers M, Kirwan J, Gossec L, Conaghan P, D'Agostino M-A, Bingham C III, et al. How to choose core outcome sets for clinical trials: OMERACT 11 approves Filter 2.0. J Rheumatol. 2014;41. in press. [PubMed: 24241481]
7. Gheita TA, Raafat H, Khalil H, Hussein H. Serum level of APRIL/BLyS in Behcet's disease patients: clinical significance in uveitis and disease activity. Mod Rheumatol. 2013; 23:542–6. [PubMed: 22752534]
8. Gheita TA, Samir H, Hussein H. Anti-annexin V antibodies in neuro-Behcet patients: clinical significance and relation to disease activity. Int J Rheum Dis. 2012; 15:e124–6. [PubMed: 23083047]
9. Yoshida A, Kaburaki T, Okinaga K, Takamoto M, Kawashima H, Fujino Y. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy. Jpn J Ophthalmol. 2012; 56:536–43. [PubMed: 23053631]
10. Melikoglu M, Melikoglu MA. The prevalence of fibromyalgia in patients with Behcet's disease and its relation with disease activity. Rheumatol Int. 2013; 33:1219–22. [PubMed: 23052486]
11. Mohammed RH, Nasef A, Kewan HH, Al Shaar M. Vascular neurobehcet disease: correlation with current disease activity forum and systemic vascular involvement. Clin Rheumatol. 2012; 31:1033–40. [PubMed: 22415466]
12. Tascilar NF, Tekin NS, Ankarali H, Sezer T, Atik L, Emre U, et al. Sleep disorders in Behcet's disease, and their relationship with fatigue and quality of life. J Sleep Res. 2012; 21:281–8. [PubMed: 22004346]
13. Han EC, Cho SB, Ahn KJ, Oh SH, Kim J, Kim DS, et al. Expression of pro-inflammatory protein S100A12 (EN-RAGE) in Behcet's disease and its association with disease activity: a pilot study. Ann Dermatol. 2011; 23:313–20. [PubMed: 21909201]

14. Ozden MG, Cayci YT, Tekin H, Coban AY, Aydin F, Senturk N, et al. Serum galectin-3 levels in patients with Behcet's disease: association with disease activity over a long-term follow-up. *J Eur Acad Dermatol Venereol*. 2011; 25:1168–73. [PubMed: 21214630]
15. Deuter CM, Zierhut M, Mohle A, Vonthein R, Stobiger N, Kotter I. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet's disease. *Arthritis Rheum*. 2010; 62:2796–805. [PubMed: 20518075]
16. Giardina A, Ferrante A, Ciccio F, Vadala M, Giardina E, Triolo G. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcet's disease refractory to standard immunosuppressive drugs. *Rheumatol Int*. 2011; 31:33–7. [PubMed: 19859715]
17. Melikoglu MA, Melikoglu M. The relationship between disease activity and depression in patients with Behcet disease and rheumatoid arthritis. *Rheumatol Int*. 2010; 30:941–6. [PubMed: 19657642]
18. Shahram F, Khabbazi A, Nadji A, Ziaie N, Banihashemi AT, Davatchi F. Comparison of existing disease activity indices in the follow-up of patients with Behcet's disease. *Mod Rheumatol*. 2009; 19:536–41. [PubMed: 19590934]
19. Yi SW, Kim JH, Lim KY, Bang D, Lee S, Lee ES. The Behcet's Disease Quality of Life: reliability and validity of the Korean version. *Yonsei Med J*. 2008; 49:698–704. [PubMed: 18972588]
20. Simsek I, Meric C, Erdem H, Pay S, Kilic S, Dinc A. Accuracy of recall of the items included in disease activity forms of Behcet's disease: comparison of retrospective questionnaires with a daily telephone interview. *Clin Rheumatol*. 2008; 27:1255–60. [PubMed: 18446267]
21. Neves FS, Moraes JC, Kowalski SC, Goldenstein-Schainberg C, Lage LV, Goncalves CR. Cross-cultural adaptation of the Behcet's Disease Current Activity Form (BDCAF) to Brazilian Portuguese language. *Clin Rheumatol*. 2007; 26:1263–7. [PubMed: 17180637]
22. Kwon SR, Lim MJ, Park SG, Moon YS, Park W. Decreased protein S activity is related to the disease activity of Behcet's disease. *Rheumatol Int*. 2006; 27:39–43. [PubMed: 16969634]
23. Bodur H, Borman P, Ozdemir Y, Atan C, Kural G. Quality of life and life satisfaction in patients with Behcet's disease: relationship with disease activity. *Clin Rheumatol*. 2006; 25:329–33. [PubMed: 16267609]
24. Musabak U, Pay S, Erdem H, Simsek I, Pekel A, Dinc A, et al. Serum interleukin-18 levels in patients with Behcet's disease. Is its expression associated with disease activity or clinical presentations? *Rheumatol Int*. 2006; 26:545–50. [PubMed: 16205927]
25. Kotter I, Vonthein R, Zierhut M, Eckstein AK, Ness T, Gunaydin I, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. *Semin Arthritis Rheum*. 2004; 33:311–9. [PubMed: 15079762]
26. Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behcet's disease activity index. *Rheumatology*. 2004; 43:73–8. [PubMed: 12890862]
27. Akarsu M, Demirkan F, Ozsan GH, Onen F, Yuksel F, Ozkan S, et al. Increased levels of tissue factor pathway inhibitor may reflect disease activity and play a role in thrombotic tendency in Behcet's disease. *Am J Hematol*. 2001; 68:225–30. [PubMed: 11754410]
28. Hamuryudan V, Fresko I, Direskeneli H, Tenant MJ, Yurdakul S, Akoglu T, et al. Evaluation of the Turkish translation of a disease activity form for Behcet's syndrome. *Rheumatology*. 1999; 38:734–6. [PubMed: 10501421]
29. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behcet's disease: evaluation of a new instrument to measure clinical activity. *Rheumatology*. 1999; 38:728–33. [PubMed: 10501420]
30. Furuta S, Chow Y, Chaudhry A, Jayne D. Switching of anti-TNF- α agents in Behcet's disease. *Clin Exp Rheumatol*. 2012; 30(Suppl 72):62–8.
31. Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, Shahram F, Nadji A, Shams H, et al. Colchicine versus placebo in Behcet's disease: randomized, double-blind, controlled crossover trial. *Mod Rheumatol*. 2009; 19:542–9. [PubMed: 19597921]
32. Harzallah O, Kerkeni A, Baati T, Mahjoub S. Oxidative stress: correlation with Behcet's disease duration, activity and severity. *Eur J Intern Med*. 2008; 19:541–7. [PubMed: 19013385]

33. Najim RA, Sharquie KE, Abu-Raghif AR. Oxidative stress in patients with Behcet's disease: I correlation with severity and clinical parameters. *J Dermatol.* 2007; 34:308–14. [PubMed: 17408439]
34. Sharquie KE, Najim RA, Al-Dori WS, Al-Hayani RK. Oral zinc sulfate in the treatment of Behcet's disease: a double blind cross-over study. *J Dermatol.* 2006; 33:541–6. [PubMed: 16923135]
35. Al-Waiz MM, Sharquie KE, A-Qaissi MH, Hayani RK. Colchicine and benzathine penicillin in the treatment of Behcet disease: a case comparative study. *Dermatol Online J.* 2005; 11:3. [PubMed: 16409899]
36. Triolo G, Accardo-Palumbo A, Dieli F, Ciccio F, Ferrante A, Giardina E, et al. Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behcet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease. *Arthritis Res Ther.* 2003; 5:R262–8. [PubMed: 12932289]
37. Adler YD, Mansmann U, Zouboulis CC. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behcet's disease. *Dermatology.* 2001; 203:322–4. [PubMed: 11752821]
38. Bassyouni IH, El-Wakd MM, Bassyouni RH. Soluble levels of osteopontin in patients with Behcet's disease: association with disease activity and vascular involvement. *J Clin Immunol.* 2013; 33:361–7. [PubMed: 23097037]
39. Mumcu G, Cimilli H, Karacayli U, Inanc N, Ture-Ozdemir F, Eksioglu-Demiralp E, et al. Salivary levels of HNP 1-3 are related to oral ulcer activity in Behcet's disease. *Int J Dermatol.* 2013; 52:1198–201. [PubMed: 22861387]
40. Orem A, Yayli S, Arica DA, Akcan B, Yucesan FB, Bahadir S. Lipoprotein-associated phospholipase A(2) level in patients with Behcet's disease. *J Eur Acad Dermatol Venereol.* Jul 3.2012 (E-pub ahead of print).
41. Cimen F, Yildirmak ST, Ergen A, Cakmak M, Dogan S, Yenice N, et al. Serum lipid, lipoprotein and oxidatively modified low density lipoprotein levels in active or inactive patients with Behcet's disease. *Indian J Dermatol.* 2012; 57:97–101. [PubMed: 22615503]
42. Kato Y, Yamamoto T. Serum levels of GRO-alpha are elevated in association with disease activity in patients with Behcet's disease. *Int J Dermatol.* 2012; 51:286–9. [PubMed: 22348563]
43. Sahin E, Karaman G, Uslu M, Karul A, Sendur N, Savk E. Adiponectin levels, insulin resistance and their relationship with serum levels of inflammatory cytokines in patients with Behcet's disease. *J Eur Acad Dermatol Venereol.* 2012; 26:1498–502. [PubMed: 22035239]
44. Ekinci NS, Alpsoy E, Karakas AA, Yilmaz SB, Yegin O. IL-17A has an important role in the acute attacks of Behcet's disease. *J Invest Dermatol.* 2010; 130:2136–8. [PubMed: 20445554]
45. Fadini GP, Tognon S, Rodriguez L, Boscaro E, Baesso I, Avogaro A, et al. Low levels of endothelial progenitor cells correlate with disease duration and activity in patients with Behcet's disease. *Clin Exp Rheumatol.* 2009; 27:814–21. [PubMed: 19917165]
46. Ertam I, Kitapcioglu G, Aksu K, Keser G, Ozaksar A, Elbi H, et al. Quality of life and its relation with disease severity in Behcet's disease. *Clin Exp Rheumatol.* 2009; 27(Suppl 53):S18–22. [PubMed: 19796527]
47. Erturan I, Basak PY, Ozturk O, Ceyhan AM, Akkaya VB. Is there any relationship between serum and urine neopterin and serum interferon-gamma levels in the activity of Behcet's disease? *J Eur Acad Dermatol Venereol.* 2009; 23:1414–8. [PubMed: 19522774]
48. Serarslan G, Sogut S, Yonden Z, Oksuz H, Savas N, Yenin JZ, et al. Increased macrophage migration inhibitory factor in Behcet's disease and relation with the disease activity. *J Eur Acad Dermatol Venereol.* 2009; 23:1344–6. [PubMed: 19368607]
49. Kutlay S, Calayoglu R, Boyvat A, Turkcapar N, Sengul S, Keven K, et al. Circulating endothelial cells: a disease activity marker in Behcet's vasculitis? *Rheumatol Int.* 2008; 29:159–62. [PubMed: 18685852]
50. Turan B, Pfister K, Diener PA, Hell M, Moller B, Boyvat A, et al. Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behcet's disease. *Scand J Rheumatol.* 2008; 37:135–41. [PubMed: 18415772]

51. Lee YJ, Kang SW, Song JK, Park JJ, Bae YD, Lee EY, et al. Serum galectin-3 and galectin-3 binding protein levels in Behcet's disease and their association with disease activity. *Clin Exp Rheumatol*. 2007; 25(Suppl 45):S41–5. [PubMed: 17949550]
52. Protogerou AD, Sfrikakis PP, Stamatelopoulou KS, Papamichael C, Aznaouridis K, Karatzis E, et al. Interrelated modulation of endothelial function in Behcet's disease by clinical activity and corticosteroid treatment. *Arthritis Res Ther*. 2007; 9:R90. [PubMed: 17845731]
53. Gullu H, Caliskan M, Erdogan D, Yilmaz S, Dursun R, Ciftci O, et al. Patients with Behcet's disease carry a higher risk for microvascular involvement in active disease period. *Ann Med*. 2007; 39:154–9. [PubMed: 17453678]
54. Sarican T, Ayabakan H, Turkmen S, Kalaslioglu V, Baran F, Yenice N. Homocysteine: an activity marker in Behcet's disease? *J Dermatol Sci*. 2007; 45:121–6. [PubMed: 17182219]
55. Caliskan M, Yilmaz S, Yildirim E, Gullu H, Erdogan D, Ciftci O, et al. Endothelial functions are more severely impaired during active disease period in patients with Behcet's disease. *Clin Rheumatol*. 2007; 26:1074–8. [PubMed: 17089218]
56. Aki T, Karıncaoglu Y, Seyhan M, Batcioglu K. Serum substance P and calcitonin gene-related peptide levels in Behcet's disease and their association with disease activity. *Clin Exp Dermatol*. 2006; 31:583–7. [PubMed: 16716167]
57. Mumcu G, Inanc N, Ergun T, Ikiz K, Gunes M, Islek U, et al. Oral health related quality of life is affected by disease activity in Behcet's disease. *Oral Dis*. 2006; 12:145–51. [PubMed: 16476035]
58. Esmat S, El Sherif H, Anwar S, Fahmy I, Elmenyawi M, Shaker O. Lipoprotein (a) and nitrites in Behcet's disease: relationship with disease activity and vascular complications. *Eur J Dermatol*. 2006; 16:67–71. [PubMed: 16436346]
59. Coskun B, Saral Y, Godekmerdan A, Erden I, Coskun N. Activation markers in Behcet's disease. *Skinmed*. 2005; 4:282–6. [PubMed: 16282749]
60. Lee SS, Yoon HJ, Chang HK, Park KS. Fibromyalgia in Behcet's disease is associated with anxiety and depression, and not with disease activity. *Clin Exp Rheumatol*. 2005; 23(Suppl 38):S15–9. [PubMed: 16273759]
61. Turkoz Y, Evereklioglu C, Ozkiris A, Mistik S, Borlu M, Ozerol IH, et al. Serum levels of soluble P-selectin are increased and associated with disease activity in patients with Behcet's syndrome. *Mediators Inflamm*. 2005; 2005:237–41. [PubMed: 16192675]
62. Gur-Toy G, Lenk N, Yalcin B, Aksaray S, Alli N. Serum interleukin-8 as a serologic marker of activity in Behcet's disease. *Int J Dermatol*. 2005; 44:657–60. [PubMed: 16101867]
63. Duygulu F, Evereklioglu C, Calis M, Borlu M, Cekmen M, Ascioglu O. Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behcet's disease: a pilot study. *Clin Rheumatol*. 2005; 24:324–30. [PubMed: 15902528]
64. Atasoy M, Karatay S, Yildirim K, Kadi M, Erdem T, Senel K. The relationship between serum prolactin levels and disease activity in patients with Behcet's disease. *Cell Biochem Funct*. 2006; 24:353–6. [PubMed: 15898123]
65. Ates A, Kinikli G, Duzgun N, Duman M. Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Behcet's disease. *Rheumatol Int*. 2006; 26:348–53. [PubMed: 15875188]
66. Calis M, Ates F, Yazici C, Kose K, Kirnap M, Demir M, et al. Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Behcet's disease. *Rheumatol Int*. 2005; 25:452–6. [PubMed: 15868151]
67. Yazici C, Kose K, Calis M, Demir M, Kirnap M, Ates F. Increased advanced oxidation protein products in Behcet's disease: a new activity marker? *Br J Dermatol*. 2004; 151:105–11. [PubMed: 15270878]
68. Evereklioglu C, Ozbek E, Cekmen M, Mehmet N, Duygulu F, Ozkiris A, et al. Urinary nitric oxide levels are increased and correlated with plasma concentrations in patients with Behcet's disease: is it a new urinary activity marker? *Nephrology*. 2003; 8:231–8. [PubMed: 15012709]
69. Cekmen M, Evereklioglu C, Er H, Inaloz HS, Doganay S, Turkoz Y, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet's syndrome. *Int J Dermatol*. 2003; 42:870–5. [PubMed: 14636202]

70. Sandikci R, Turkmen S, Guvenen G, Ayabakan H, Gulcan P, Koldas M, et al. Lipid peroxidation and antioxidant defence system in patients with active or inactive Behcet's disease. *Acta Derm Venereol.* 2003; 83:342–6. [PubMed: 14609100]
71. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behcet's disease patients. Relationship with disease activity. *Scand J Rheumatol.* 2002; 31:205–10. [PubMed: 12369651]
72. Evereklioglu C, Inaloz HS, Kirtak N, Doganay S, Bulbul M, Ozerol E, et al. Serum leptin concentration is increased in patients with Behcet's syndrome and is correlated with disease activity. *Br J Dermatol.* 2002; 147:331–6. [PubMed: 12174107]
73. Aygunduz M, Baybek N, Ozturk M, Kaftan O, Kosar A, Kirazli S. Serum beta 2-microglobulin reflects disease activity in Behcet's disease. *Rheumatol Int.* 2002; 22:5–8. [PubMed: 12120912]
74. Odabas AR, Karakuzu A, Cetinkaya R, Selcuk Y, Keles S, Bilen H. Increased serum ferritin levels in active Behcet's disease. *Int J Clin Pract.* 2002; 56:310–1. [PubMed: 12074217]
75. Evereklioglu C, Turkoz Y, Er H, Inaloz HS, Ozbek E, Cekmen M. Increased nitric oxide production in patients with Behcet's disease: is it a new activity marker? *J Am Acad Dermatol.* 2002; 46:50–4. [PubMed: 11756945]
76. Gurbuz O, Ozdemir Y, Cosar CB, Kural G. Lipoprotein (a) in Behcet's disease as an indicator of disease activity and in thrombotic complications. *Eur J Ophthalmol.* 2001; 11:62–5. [PubMed: 11284488]
77. Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC. Adamantiades-Behcet's disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. *Dermatology.* 2000; 201:37–9. [PubMed: 10971057]
78. Zouboulis CC, Katsantonis J, Ketteler R, Treudler R, Kaklamani E, Hornemann S, et al. Adamantiades-Behcet's disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. *Arch Dermatol Res.* 2000; 292:279–84. [PubMed: 10929768]
79. Alpsoy E, Cayirli C, Er H, Yilmaz E. The levels of plasma interleukin-2 and soluble interleukin-2R in Behcet's disease: a marker of disease activity. *J Dermatol.* 1998; 25:513–6. [PubMed: 9769596]
80. Sugi-Ikai N, Nakazawa M, Nakamura S, Ohno S, Minami M. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behcet's disease. *Invest Ophthalmol Vis Sci.* 1998; 39:996–1004. [PubMed: 9579479]
81. Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behcet's disease; soluble TNFR-75 as a biological marker of disease activity. *J Rheumatol.* 1997; 24:128–32. [PubMed: 9002023]
82. Yosipovitch G, Shohat B, Bshara J, Wysenbeek A, Weinberger A. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behcet's disease: correlations with disease activity and severity. *Isr J Med Sci.* 1995; 31:345–8. [PubMed: 7607852]
83. Aydintug AO, Tokgoz G, Ozoran K, Duzgun N, Gurler A, Tutkak H. Elevated levels of soluble intercellular adhesion molecule-1 correlate with disease activity in Behcet's disease. *Rheumatol Int.* 1995; 15:75–8. [PubMed: 7481484]
84. Cervera R, Navarro M, Lopez-Soto A, Cid MC, Font J, Esparza J, et al. Antibodies to endothelial cells in Behcet's disease: cell-binding heterogeneity and association with clinical activity. *Ann Rheum Dis.* 1994; 53:265–7. [PubMed: 8203957]
85. Muftuoglu AU, Yazici H, Yurdakul S, Tuzun Y, Pazarli H, Gungen G, et al. Behcet's disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity. *Int J Dermatol.* 1986; 25:235–9. [PubMed: 3710672]
86. Yazici H, Tuzun Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdogan H, et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behcet's syndrome. *Ann Rheum Dis.* 1984; 43:783–9. [PubMed: 6524980]
87. Yalcindag FN, Yalcindag A, Caglayan O, Ozdemir O. Serum haptoglobin levels in ocular Behcet disease and acute phase proteins in the course of Behcet disease. *Eur J Ophthalmol.* 2008; 18:787–91. [PubMed: 18850559]

88. Lee JS, Park MJ, Park S, Lee ES. Differential expression of T cell immunoglobulin- and mucin-domain-containing molecule-3 (TIM-3) according to activity of Behcet's disease. *J Dermatol Sci*. 2012; 65:220–2. [PubMed: 22336995]
89. Kose O, Arca E, Akgul O, Erbil K. The levels of serum neopterin in Behcet's disease—objective marker of disease activity. *J Dermatol Sci*. 2006; 42:128–30. [PubMed: 16600572]
90. Bank I, Duvdevani M, Livneh A. Expansion of gammadelta T-cells in Behcet's disease: role of disease activity and microbial flora in oral ulcers. *J Lab Clin Med*. 2003; 141:33–40. [PubMed: 12518166]
91. Hamzaoui K, Hamzaoui A, Zakraoui L, Chabbou A. Expression of Bcl-2 in inflammatory sites from patients with active Behcet's disease. *Mediators Inflamm*. 1999; 8:101–6. [PubMed: 10704147]
92. Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong Dle T, Amoura Z, et al. Immunosuppressants reduce venous thrombosis relapse in Behcet's disease. *Arthritis Rheum*. 2012; 64:2753–60. [PubMed: 22354392]
93. Geri G, Wechsler B, Thi Huong du L, Isnard R, Piette JC, Amoura Z, et al. Spectrum of cardiac lesions in Behcet disease: a series of 52 patients and review of the literature. *Medicine*. 2012; 91:25–34. [PubMed: 22198500]
94. Saadoun D, Asli B, Wechsler B, Houman H, Geri G, Desseaux K, et al. Long-term outcome of arterial lesions in Behcet disease: a series of 101 patients. *Medicine*. 2012; 91:18–24. [PubMed: 22198498]
95. Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Characteristics of vascular involvement in Behcet's disease in Japan: a retrospective cohort study. *Clin Exp Rheumatol*. 2011; 29(Suppl 67):S47–53. [PubMed: 21968236]
96. Koksoy C, Gyedu A, Alacayir I, Bengisun U, Uncu H, Anadol E. Surgical treatment of peripheral aneurysms in patients with Behcet's disease. *Eur J Vasc Endovasc Surg*. 2011; 42:525–30. [PubMed: 21641238]
97. Riera-Mestre A, Martinez-Yelamos S, Martinez-Yelamos A, Ferrer I, Pujol R, Vidaller A. Clinicopathologic features and outcomes of neuro-Behcet disease in Spain: a study of 20 patients. *Eur J Intern Med*. 2010; 21:536–41. [PubMed: 21111940]
98. Hamuryudan V, Hatemi G, Tascilar K, Sut N, Ozyazgan Y, Seyahi E, et al. Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial. *Rheumatology*. 2010; 49:173–7. [PubMed: 19995858]
99. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. *Medicine*. 2003; 82:60–76. [PubMed: 12544711]
100. Tuzun H, Besirli K, Sayin A, Vural FS, Hamuryudan V, Hizli N, et al. Management of aneurysms in Behcet's syndrome: an analysis of 24 patients. *Surgery*. 1997; 121:150–6. [PubMed: 9037226]
101. Yazici H, Basaran G, Hamuryudan V, Hizli N, Yurdakul S, Mat C, et al. The ten-year mortality in Behcet's syndrome. *Br J Rheumatol*. 1996; 35:139–41. [PubMed: 8612025]
102. Hamuryudan V, Yurdakul S, Moral F, Numan F, Tuzun H, Tuzuner N, et al. Pulmonary arterial aneurysms in Behcet's syndrome: a report of 24 cases. *Br J Rheumatol*. 1994; 33:48–51. [PubMed: 8162457]
103. Saadoun D, Wechsler B, Desseaux K, Le Thi Huong D, Amoura Z, Resche-Rigon M, et al. Mortality in Behcet's disease. *Arthritis Rheum*. 2010; 62:2806–12. [PubMed: 20496419]
104. Kim SK, Jang WC, Ahn YC, Lee SH, Lee SS, Hur JW. Promoter –2518 single nucleotide polymorphism of monocyte chemoattractant protein-1 is associated with clinical severity in Behcet's disease. *Inflamm Res*. 2012; 61:541–5. [PubMed: 22476561]
105. Choe JY, Chung WT, Lee SW, Lee SS, Choi CB, Park SH, et al. Regional distinction for the clinical severity of Behcet's disease in Korea: four university-based medical centers study. *Clin Exp Rheumatol*. 2010; 28(Suppl 60):S20–6. [PubMed: 20868566]
106. Arabaci T, Kara C, Cicek Y. Relationship between periodontal parameters and Behcet's disease and evaluation of different treatments for oral recurrent aphthous stomatitis. *J Periodontal Res*. 2009; 44:718–25. [PubMed: 19076988]

107. Aksu K, Kitapcioglu G, Keser G, Berdeli A, Karabulut G, Kobak S, et al. FcγRIIIa, IIIa and IIIb gene polymorphisms in Behcet's disease: do they have any clinical implications? *Clin Exp Rheumatol*. 2008; 26(Suppl 50):S77–83. [PubMed: 19026120]
108. Alpsoy E, Donmez L, Onder M, Gunasti S, Usta A, Karıncaoglu Y, et al. Clinical features and natural course of Behcet's disease in 661 cases: a multicentre study. *Br J Dermatol*. 2007; 157:901–6. [PubMed: 17711526]
109. Rozenbaum M, Boulman N, Slobodin G, Zisman D, Mader R, Yankevitch A, et al. Behcet disease in adult Druzes in north Israel: the influence of ethnic origin on disease expression and severity. *J Clin Rheumatol*. 2007; 13:124–7. [PubMed: 17551376]
110. Akman A, Kacaroglu H, Donmez L, Bacanli A, Alpsoy E. Relationship between periodontal findings and Behcet's disease: a controlled study. *J Clin Periodontol*. 2007; 34:485–91. [PubMed: 17451414]
111. Inanc N, Mumcu G, Birtas E, Elbir Y, Yavuz S, Ergun T, et al. Serum mannose-binding lectin levels are decreased in Behcet's disease and associated with disease severity. *J Rheumatol*. 2005; 32:287–91. [PubMed: 15693089]
112. Mumcu G, Ergun T, Inanc N, Fresko I, Atalay T, Hayran O, et al. Oral health is impaired in Behcet's disease and is associated with disease severity. *Rheumatology*. 2004; 43:1028–33. [PubMed: 15161982]
113. Krause I, Mader R, Sulkas J, Paul M, Uziel Y, Adawi M, et al. Behcet's disease in Israel: the influence of ethnic origin on disease expression and severity. *J Rheumatol*. 2001; 28:1033–6. [PubMed: 11361184]
114. Krause I, Rosen Y, Kaplan I, Milo G, Guedj D, Molad Y, et al. Recurrent aphthous stomatitis in Behcet's disease: clinical features and correlation with systemic disease expression and severity. *J Oral Pathol Med*. 1999; 28:193–6. [PubMed: 10226940]
115. Polat M, Vahaboglu G, Onde U, Eksioglu M. Classifying patients with Behcet's disease for disease severity, using a discriminating analysis method. *Clin Exp Dermatol*. 2009; 34:151–5. [PubMed: 19187295]
116. Park SH, Park KS, Seo YI, Min DJ, Kim WU, Kim TG, et al. Association of MICA polymorphism with HLA-B*51 and disease severity in Korean patients with Behcet's disease. *J Korean Med Sci*. 2002; 17:366–70. [PubMed: 12068141]
117. Gul A, Uyar FA, Inanc M, Ocal L, Tugal-Tutkun I, Aral O, et al. Lack of association of HLA-B*51 with a severe disease course in Behcet's disease. *Rheumatology*. 2001; 40:668–72. [PubMed: 11426025]
118. Fani MM, Ebrahimi H, Pourshahidi S, Aflaki E, Shafiee Sarvestani S. Comparing the effect of phenytoin syrup and triamcinolone acetonide ointment on aphthous ulcers in patients with Behcet's syndrome. *Iran Red Crescent Med J*. 2012; 14:75–8. [PubMed: 22737559]
119. Qiao H, Sonoda KH, Ariyama A, Kuratomi Y, Kawano Y, Ishibashi T. CXCR2 Expression on neutrophils is upregulated during the relapsing phase of ocular Behcet disease. *Curr Eye Res*. 2005; 30:195–203. [PubMed: 15804745]
120. Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. *Arch Dermatol*. 2002; 138:467–71. [PubMed: 11939808]
121. Uzun S, Alpsoy E, Durdu M, Akman A. The clinical course of Behcet's disease in pregnancy: a retrospective analysis and review of the literature. *J Dermatol*. 2003; 30:499–502. [PubMed: 12928538]
122. Hamuryudan V, Hatemi G, Sut N, Ugurlu S, Yurdakul S, Yazici H. Frequent oral ulceration during early disease may predict a severe disease course in males with Behcet's syndrome. *Clin Exp Rheumatol*. 2012; 30(Suppl 72):32–4.
123. Arida A, Fragiadaki K, Giavri E, Sfrikakis PP. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. *Semin Arthritis Rheum*. 2011; 41:61–70. [PubMed: 21168186]
124. Gilworth G, Chamberlain MA, Bhakta B, Haskard D, Silman A, Tennant A. Development of the BD-QoL: a quality of life measure specific to Behcet's disease. *J Rheumatol*. 2004; 31:931–7. [PubMed: 15124253]

125. Touma Z, Ghandour L, Sibai A, Puzantian H, Hamdan A, Hamdan O, et al. Cross-cultural adaptation and validation of Behcet's disease quality of life questionnaire. *BMC Med Res Methodol*. 2011; 11:52. [PubMed: 21507231]
126. Mumcu G, Sur H, Inanc N, Karacayli U, Cimilli H, Sisman N, et al. A composite index for determining the impact of oral ulcer activity in Behcet's disease and recurrent aphthous stomatitis. *J Oral Pathol Med*. 2009; 38:785–91. [PubMed: 19614861]
127. Karacayli U, Mumcu G, Simsek I, Pay S, Kose O, Erdem H, et al. The close association between dental and periodontal treatments and oral ulcer course in Behcet's disease: a prospective clinical study. *J Oral Pathol Med*. 2009; 38:410–5. [PubMed: 19320802]
128. Mumcu G, Niazi S, Stewart J, Hagi-Pavli E, Gokani B, Seoudi N, et al. Oral health and related quality of life status in patients from UK and Turkey: a comparative study in Behcet's disease. *J Oral Pathol Med*. 2009; 38:406–9. [PubMed: 19298505]
129. Chams-Davatchi C, Barikbin B, Shahram F, Nadji A, Moghaddassi M, Yousefi M, et al. Pimecrolimus versus placebo in genital aphthous ulcers of Behcet's disease: a randomized double-blind controlled trial. *Int J Rheum Dis*. 2010; 13:253–8. [PubMed: 20704623]
130. Kose O, Dinc A, Simsek I. Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Behcet's disease. *Dermatology*. 2009; 218:140–5. [PubMed: 19060462]
131. Mumcu G, Hayran O, Ozalp DO, Inanc N, Yavuz S, Ergun T, et al. The assessment of oral health-related quality of life by factor analysis in patients with Behcet's disease and recurrent aphthous stomatitis. *J Oral Pathol Med*. 2007; 36:147–52. [PubMed: 17305636]
132. Mat C, Yurdakul S, Uysal S, Gogus F, Ozyazgan Y, Uysal O, et al. A double-blind trial of depot corticosteroids in Behcet's syndrome. *Rheumatology*. 2006; 45:348–52. [PubMed: 16263779]
133. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. *J Rheumatol*. 2005; 32:98–105. [PubMed: 15630733]
134. Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study. *Drugs R D*. 2003; 4:19–28. [PubMed: 12568631]
135. Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behcet's disease: a double-blind, placebo-controlled, cross-over study. *J Dermatol*. 2002; 29:267–79. [PubMed: 12081158]
136. Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, et al. A double-blind trial of colchicine in Behcet's syndrome. *Arthritis Rheum*. 2001; 44:2686–92. [PubMed: 11710724]
137. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 1998; 128:443–50. [PubMed: 9499327]
138. Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet's disease. *Dermatology*. 1996; 192:125–8. [PubMed: 8829493]
139. Hamuryudan V, Moral F, Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, et al. Systemic interferon alpha 2b treatment in Behcet's syndrome. *J Rheumatol*. 1994; 21:1098–100. [PubMed: 7932420]
140. Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y, et al. A double blind study of colchicine in Behcet's disease. *Haematologica*. 1980; 65:399–402. [PubMed: 6778795]
141. Gur A, Sarac AJ, Burkan YK, Nas K, Cevik R. Arthropathy, quality of life, depression, and anxiety in Behcet's disease: relationship between arthritis and these factors. *Clin Rheumatol*. 2006; 25:524–31. [PubMed: 16639519]
142. Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet's disease. A randomized clinical trial. *Arthritis Rheum*. 1996; 39:2062–5.
143. Moral F, Hamuryudan V, Yurdakul S, Yazici H. Inefficacy of azapropazone in the acute arthritis of Behcet's syndrome: a randomized, double blind, placebo controlled study. *Clin Exp Rheumatol*. 1995; 13:493–5. [PubMed: 7586783]

144. Hu K, Lei B, Kijlstra A, Li P, Zhang X, Xiao X, et al. Male sex, erythema nodosum, and electroretinography as predictors of visual prognosis after cataract surgery in patients with Behcet disease. *J Cataract Refract Surg*. 2012; 38:1382–8. [PubMed: 22727990]
145. Okada AA, Goto H, Ohno S, Mochizuki M. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. *Arch Ophthalmol*. 2012; 130:592–8. [PubMed: 22652845]
146. Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, Cordero-Coma M, Ortega G, Ortego N, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. *Ophthalmology*. 2012; 119:1575–81. [PubMed: 22525047]
147. Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassara E, Susini M, et al. Efficacy of infliximab in refractory Behcet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. *Biologics*. 2012; 6:5–12. [PubMed: 22291462]
148. Taylor SR, Singh J, Menezes V, Wakefield D, McCluskey P, Lightman S. Behcet disease: visual prognosis and factors influencing the development of visual loss. *Am J Ophthalmol*. 2011; 152:1059–66. [PubMed: 21872204]
149. Chu M, Yang P, Hou S, Li F, Chen Y, Kijlstra A. Behcet's disease exhibits an increased osteopontin serum level in active stage but no association with osteopontin and its receptor gene polymorphisms. *Hum Immunol*. 2011; 72:525–9. [PubMed: 21513757]
150. Onal S, Kazokoglu H, Koc A, Akman M, Bavbek T, Direskeneli H, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. *Arch Ophthalmol*. 2011; 129:288–94. [PubMed: 21402983]
151. Onal S, Savar F, Akman M, Kazokoglu H. Vision- and health-related quality of life in patients with Behcet uveitis. *Arch Ophthalmol*. 2010; 128:1265–71. [PubMed: 20937995]
152. Davatchi F, Shahram F, Shams H, Nadji A, Chams-Davatchi C, Akhlaghi M, et al. Gender influence on ocular manifestations and their outcome in Behcet's Disease. A long-term follow-up of up to 20 years. *Clin Rheumatol*. 2011; 30:541–7. [PubMed: 20857156]
153. Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, et al. Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). *Int J Rheum Dis*. 2010; 13:246–52. [PubMed: 20704622]
154. Saadoun D, Wechsler B, Terrada C, Hajage D, Le Thi Huong D, Resche-Rigon M, et al. Azathioprine in severe uveitis of Behcet's disease. *Arthritis Care Res*. 2010; 62:1733–8.
155. Sobaci G, Erdem U, Durukan AH, Erdurman C, Bayer A, Koksall S, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments. *Ophthalmology*. 2010; 117:1430–5. [PubMed: 20417563]
156. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. *Br J Ophthalmol*. 2010; 94:284–8. [PubMed: 19692382]
157. Kramer M, Amer R, Mukamel M, Snir M, Jaouni T, Friling R. Uveitis in juvenile Behcet's disease: clinical course and visual outcome compared with adult patients. *Eye (Lond)*. 2009; 23:2034–41. [PubMed: 19151650]
158. Gueudry J, Wechsler B, Terrada C, Gendron G, Cassoux N, Fardeau C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. *Am J Ophthalmol*. 2008; 146:837–44. e1. [PubMed: 19027420]
159. Kump LI, Moeller KL, Reed GF, Kurup SK, Nussenblatt RB, Levy-Clarke GA. Behcet's disease: comparing 3 decades of treatment response at the National Eye Institute. *Can J Ophthalmol*. 2008; 43:468–72. [PubMed: 18711463]
160. Cho YJ, Kim WK, Lee JH, Byeon SH, Koh HJ, Kwon OW, et al. Visual prognosis and risk factors for Korean patients with Behcet uveitis. *Ophthalmologica*. 2008; 222:344–50. [PubMed: 18635932]
161. Krause L, Altenburg A, Pleyer U, Kohler AK, Zouboulis CC, Foerster MH. Longterm visual prognosis of patients with ocular Adamantiades-Behcet's disease treated with interferon-alpha-2a. *J Rheumatol*. 2008; 35:896–903. [PubMed: 18412306]
162. Yalcindag FN, Can E, Ozdemir O. Intravenous methylprednisolone pulse therapy for acute posterior segment uveitis attacks in Behcet's disease. *Ann Ophthalmol (Skokie)*. 2007; 39:194–7. [PubMed: 18025624]

163. Salvarani C, Pipitone N, Catanoso MG, Cimino L, Tumiatì B, Macchioni P, et al. Epidemiology and clinical course of Behcet's disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study. *Arthritis Rheum.* 2007; 57:171–8. [PubMed: 17266063]
164. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. *Graefes Arch Clin Exp Ophthalmol.* 2006; 244:1692–5. [PubMed: 16673135]
165. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. *Arthritis Rheum.* 2005; 52:2478–84. [PubMed: 16052571]
166. Takeuchi M, Hokama H, Tsukahara R, Kezuka T, Goto H, Sakai J, et al. Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement. *Graefes Arch Clin Exp Ophthalmol.* 2005; 243:1147–52. [PubMed: 15983811]
167. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behcet disease: an analysis of 880 patients. *Am J Ophthalmol.* 2004; 138:373–80. [PubMed: 15364218]
168. Lashay AR, Rahimi A, Chams H, Davatchi F, Shahram F, Hatmi ZN, et al. Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcet's disease. *Eye (Lond).* 2003; 17:762–6. [PubMed: 12928692]
169. Calguneri M, Ozturk MA, Ertenli I, Kiraz S, Apras S, Ozbalkan Z. Effects of interferon alpha treatment on the clinical course of refractory Behcet's disease: an open study. *Ann Rheum Dis.* 2003; 62:492–3. [PubMed: 12695172]
170. Ozdal PC, Ortac S, Taskintuna I, Firat E. Long-term therapy with low dose cyclosporin A in ocular Behcet's disease. *Doc Ophthalmol.* 2002; 105:301–12. [PubMed: 12539855]
171. Ozerturk Y, Bardak Y, Durmus M. Vitreoretinal surgery in Behcet's disease with severe ocular complications. *Acta Ophthalmol Scand.* 2001; 79:192–6. [PubMed: 11284762]
172. Ando K, Fujino Y, Hijikata K, Izawa Y, Masuda K. Epidemiological features and visual prognosis of Behcet's disease. *Jpn J Ophthalmol.* 1999; 43:312–7. [PubMed: 10482479]
173. Fujino Y, Joko S, Masuda K, Yagi I, Kogure M, Sakai J, et al. Cyclosporin microemulsion pre-concentrate treatment of patients with Behcet's disease. *Jpn J Ophthalmol.* 1999; 43:318–26. [PubMed: 10482480]
174. Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. *Arthritis Rheum.* 1997; 40:769–74. [PubMed: 9125262]
175. Sakamoto M, Akazawa K, Nishioka Y, Sanui H, Inomata H, Nose Y. Prognostic factors of vision in patients with Behcet disease. *Ophthalmology.* 1995; 102:317–21. [PubMed: 7862420]
176. Palmares J, Castro-Correia J, Coutinho MF, Araujo D, Delgado L. Immunosuppression in Behcet's disease Clinical management and long-term visual outcome. *Ocul Immunol Inflamm.* 1995; 3:99–106. [PubMed: 22827276]
177. Ouazzani B, Bencheikroun N, el Aouni A, Hajji Z, Chaoui Z, Berraho-Hamani A. Résultat de la maladie de Behçet dans la pratique ophtalmologique au Maroc [French]. Outcome of Behcet disease in ophthalmologic practice in Morocco. *J Fr Ophtalmol.* 1995; 18:373–5. [PubMed: 7560773]
178. Hayasaka S, Kawamoto K, Noda S, Kodama T. Visual prognosis in patients with Behcet's disease receiving colchicine, systemic corticosteroid or cyclosporin. *Ophthalmologica.* 1994; 208:210–3. [PubMed: 7970549]
179. Sajjadi H, Soheilian M, Ahmadi H, Hassanein K, Parvin M, Azarmina M, et al. Low dose cyclosporin-A therapy in Behcet's disease. *J Ocul Pharmacol.* 1994; 10:553–60. [PubMed: 7836864]
180. Towler HM, Lightman S. Visual prognosis in Behcet's disease. *Ocul Immunol Inflamm.* 1993; 1:249–54. [PubMed: 22822780]
181. Ozyazgan Y, Yurdakul S, Yazici H, Tuzun B, Iscimen A, Tuzun Y, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. *Br J Ophthalmol.* 1992; 76:241–3. [PubMed: 1390495]

182. Cochereau-Massin I, Wechsler B, Le Hoang P, Le Thi Huong D, Girard B, Rousselle F, et al. Pronostic oculaire dans la maladie de Behçet [French]. Ocular prognosis in Behcet's disease. *J Fr Ophthalmol*. 1992; 15:343–7. [PubMed: 1430813]
183. Mochizuki M, Masuda K, Sakane T, Inaba G, Ito K, Kogure M, et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behcet's disease. Japanese FK 506 Study Group on Refractory Uveitis. *Transplant Proc*. 1991; 23:3343–6. [PubMed: 1721456]
184. Kazokoglu H, Saatci O, Cuhadaroglu H, Eldem B. Long-term effects of cyclophosphamide and colchicine treatment in Behcet's disease. *Ann Ophthalmol*. 1991; 23:148–51. [PubMed: 2064258]
185. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behcet's syndrome. *N Engl J Med*. 1990; 322:281–5. [PubMed: 2404204]
186. Benezra D, Cohen E. Treatment and visual prognosis in Behcet's disease. *Br J Ophthalmol*. 1986; 70:589–92. [PubMed: 3741823]
187. Pivetti Pezzi P, Gasparri V, De Liso P, Catarinelli G. Prognosis in Behcet's disease. *Ann Ophthalmol*. 1985; 17:20–5. [PubMed: 3977213]
188. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine therapy for uveitis: long-term followup. *J Ocul Pharmacol*. 1985; 1:369–82. [PubMed: 3880086]
189. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. *Lancet*. 1989; 1:1093–6. [PubMed: 2566048]
190. BenEzra D, Cohen E, Chajek T, Friedman G, Pizanti S, de Courten C, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. *Transplant Proc*. 1988; 20(Suppl 4):136–43. [PubMed: 3381269]
191. Simonini G, Taddio A, Cattalini M, Caputo R, De Libero C, Naviglio S, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. *Arthritis Care Res*. 2011; 63:612–8.
192. Sugita S, Yamada Y, Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease. *Br J Ophthalmol*. 2011; 95:549–52. [PubMed: 20584716]
193. Usui Y, Takeuchi M, Yamakawa N, Takeuchi A, Kezuka T, Ma J, et al. Expression and function of inducible costimulator on peripheral blood CD4+ T cells in Behcet's patients with uveitis: a new activity marker? *Invest Ophthalmol Vis Sci*. 2010; 51:5099–104. [PubMed: 20445113]
194. Yamada Y, Sugita S, Tanaka H, Kamoi K, Takase H, Mochizuki M. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment. *Br J Ophthalmol*. 2011; 95:205–8. [PubMed: 20542984]
195. Mudun BA, Ergen A, Ipcioglu SU, Burumcek EY, Durlu Y, Arslan MO. Short-term chlorambucil for refractory uveitis in Behcet's disease. *Ocul Immunol Inflamm*. 2001; 9:219–29. [PubMed: 11935432]
196. Sakane T, Mochizuki M, Inaba G, Masuda K. A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behcet's disease and allied conditions [Japanese]. *Ryumachi*. 1995; 35:802–13. [PubMed: 8594659]
197. Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS. Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. *Clin Rheumatol*. 2008; 27:201–5. [PubMed: 17636362]
198. Cho SB, Kim T, Cho S, Shim WH, Yang MS, Bang D. Major arterial aneurysms and pseudoaneurysms in Behcet's disease: results from a single centre. *Scand J Rheumatol*. 2011; 40:64–7. [PubMed: 20840016]
199. Kim WH, Choi D, Kim JS, Ko YG, Jang Y, Shim WH. Effectiveness and safety of endovascular aneurysm treatment in patients with vasculo-Behcet disease. *J Endovasc Ther*. 2009; 16:631–6. [PubMed: 19842735]
200. Park MC, Hong BK, Kwon HM, Hong YS. Surgical outcomes and risk factors for postoperative complications in patients with Behcet's disease. *Clin Rheumatol*. 2007; 26:1475–80. [PubMed: 17235654]

201. Tuzun H, Seyahi E, Arslan C, Hamuryudan V, Besirli K, Yazici H. Management and prognosis of nonpulmonary large arterial disease in patients with Behcet disease. *J Vasc Surg.* 2012; 55:157–63. [PubMed: 21944910]
202. Zhu Y, Wu Q, Guo L, Fang L, Yan X, Zhang F, et al. The clinical characteristics and outcome of intracardiac thrombus and aortic valvular involvement in Behçet's disease: an analysis of 20 cases. *Clin Exp Rheumatol.* 2012; 30(Suppl 72):40–5.
203. Ha Y, Jung S, Lee K, Jung S, Lee S, Park M, et al. Long-term clinical outcomes and risk factors for the occurrence of post-operative complications after cardiovascular surgery in patients with Behcet's disease. *Clin Exp Rheumatol.* 2012; 30(Suppl 72):18–26. [PubMed: 23020850]
204. Ait Ben Haddou EH, Imounan F, Regragui W, Mouti O, Benchakroune N, Abouqal R, et al. Neurological manifestations of Behcet's disease: evaluation of 40 patients treated by cyclophosphamide. *Rev Neurol (Paris).* 2012; 168:344–9. [PubMed: 22136880]
205. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients. The Neuro-Behcet Study Group. *Brain.* 1999; 122(Pt 11):2171–82. [PubMed: 10545401]
206. Akman-Demir G, Tuzun E, Icoz S, Yesilot N, Yentur SP, Kurtuncu M, et al. Interleukin-6 in neuro-Behcet's disease: association with disease subsets and long-term outcome. *Cytokine.* 2008; 44:373–6. [PubMed: 19010690]
207. Evcik D, Dogan SK, Ay S, Cuzdan N, Guven M, Gurler A, et al. Does Behcet's disease associate with neuropathic pain syndrome and impaired well-being? *Clin Rheumatol.* 2013; 32:33–6. [PubMed: 23001467]
208. Gunduz T, Emir O, Kurtuncu M, Mutlu M, Tumac A, Akca S, et al. Cognitive impairment in neuro-Behcet's disease and multiple sclerosis: a comparative study. *Int J Neurosci.* 2012; 122:650–6. [PubMed: 22720779]
209. Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, et al. Behcet's disease: diagnostic and prognostic aspects of neurological involvement. *J Neurol.* 2001; 248:95–103. [PubMed: 11284141]
210. Yesilot N, Mutlu M, Gungor O, Baykal B, Serdaroglu P, Akman-Demir G. Clinical characteristics and course of spinal cord involvement in Behcet's disease. *Eur J Neurol.* 2007; 14:729–37. [PubMed: 17594327]
211. Cheon JH, Han DS, Park JY, Ye BD, Jung SA, Park YS, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet's disease. *Inflamm Bowel Dis.* 2011; 17:605–13. [PubMed: 20848515]
212. Choi CH, Kim TI, Kim BC, Shin SJ, Lee SK, Kim WH, et al. Anti-Saccharomyces cerevisiae antibody in intestinal Behcet's disease patients: relation to clinical course. *Dis Colon Rectum.* 2006; 49:1849–59. [PubMed: 17080284]
213. Choi IJ, Kim JS, Cha SD, Jung HC, Park JG, Song IS, et al. Long-term clinical course and prognostic factors in intestinal Behcet's disease. *Dis Colon Rectum.* 2000; 43:692–700. [PubMed: 10826433]
214. Chung MJ, Cheon JH, Kim SU, Park JJ, Kim TI, Kim NK, et al. Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behcet disease. *J Clin Gastroenterol.* 2010; 44:e116–22. [PubMed: 20054283]
215. Jung YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease. *Inflamm Bowel Dis.* 2012; 18:750–7. [PubMed: 21618352]
216. Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behcet's disease during the first five years. *Dig Dis Sci.* 2013; 58:496–503. [PubMed: 22899244]
217. Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Long-term clinical outcomes of Crohn's disease and intestinal Behcet's disease. *Inflamm Bowel Dis.* 2013; 19:99–105. [PubMed: 22508364]
218. Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. *J Clin Gastroenterol.* 2012; 46:e38–45. [PubMed: 22298088]

219. Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Early versus late surgery in patients with intestinal Behcet disease. *Dis Colon Rectum*. 2012; 55:65–71. [PubMed: 22156869]
220. Jung YS, Kim SW, Yoon JY, Lee JH, Jeon SM, Hong SP, et al. Expression of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) correlates with clinical disease activity in intestinal Behcet's disease. *Inflamm Bowel Dis*. 2011; 17:2130–7. [PubMed: 21910175]
221. Jung YS, Yoon JY, Hong SP, Kim TI, Kim WH, Cheon JH. Influence of age at diagnosis and sex on clinical course and long-term prognosis of intestinal Behcet's disease. *Inflamm Bowel Dis*. 2012; 18:1064–71. [PubMed: 21793128]
222. Jung YS, Yoon JY, Lee JH, Jeon SM, Hong SP, Kim TI, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. *Inflamm Bowel Dis*. 2011; 17:1594–602. [PubMed: 21674717]
223. Kim JS, Lim SH, Choi IJ, Moon H, Jung HC, Song IS, et al. Prediction of the clinical course of Behcet's colitis according to macroscopic classification by colonoscopy. *Endoscopy*. 2000; 32:635–40. [PubMed: 10935793]
224. Kim WH, Cho YS, Yoo HM, Park IS, Park EC, Lim JG. Quality of life in Korean patients with inflammatory bowel diseases: ulcerative colitis, Crohn's disease and intestinal Behcet's disease. *Int J Colorectal Dis*. 1999; 14:52–7. [PubMed: 10207731]
225. Lee KS, Kim SJ, Lee BC, Yoon DS, Lee WJ, Chi HS. Surgical treatment of intestinal Behcet's disease. *Yonsei Med J*. 1997; 38:455–60. [PubMed: 9509916]
226. Naganuma M, Iwao Y, Inoue N, Hisamatsu T, Imaeda H, Ishii H, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behcet's disease. *Am J Gastroenterol*. 2000; 95:2848–51. [PubMed: 11051358]
227. Shin SJ, Kim BC, Kim TI, Lee SK, Lee KH, Kim WH. Anti-alpha-enolase antibody as a serologic marker and its correlation with disease severity in intestinal Behcet's disease. *Dig Dis Sci*. 2011; 56:812–8. [PubMed: 20632102]
228. Gul IG, Kartalci S, Cumurcu BE, Karıncaoglu Y, Yologlu S, Karlidag R. Evaluation of sexual function in patients presenting with Behcet's disease with or without depression. *J Eur Acad Dermatol Venereol*. 2013; 27:1244–51. [PubMed: 23003681]
229. Bernabe E, Marcenes W, Mather J, Phillips C, Fortune F. Impact of Behcet's syndrome on health-related quality of life: influence of the type and number of symptoms. *Rheumatology*. 2010; 49:2165–71. [PubMed: 20675710]
230. Calikoglu E, Onder M, Cosar B, Candansayar S. Depression, anxiety levels and general psychological profile in Behcet's disease. *Dermatology*. 2001; 203:238–40. [PubMed: 11701978]
231. Cavaco S, da Silva AM, Pinto P, Coutinho E, Santos E, Bettencourt A, et al. Cognitive functioning in Behcet's disease. *Ann N Y Acad Sci*. 2009; 1173:217–26. [PubMed: 19758154]
232. Erberk-Ozen N, Birol A, Boratav C, Kocak M. Executive dysfunctions and depression in Behcet's disease without explicit neurological involvement. *Psychiatry Clin Neurosci*. 2006; 60:465–72. [PubMed: 16884449]
233. Gurbuzler L, Inanir A, Yelken K, Koc S, Eyibilen A, Uysal IO, et al. Behcet's disease impairs voice quality without laryngeal and hypopharyngeal involvement. *Eur Arch Otorhinolaryngol*. 2012; 269:2539–42. [PubMed: 22763430]
234. Hayran O, Mumcu G, Inanc N, Ergun T, Direskeneli H. Assessment of minimal clinically important improvement by using Oral Health Impact Profile-14 in Behcet's disease. *Clin Exp Rheumatol*. 2009; 27(Suppl 53):S79–84. [PubMed: 19796539]
235. Hiz O, Ediz L, Gulcu E, Tekeoglu I. Effects of Behcet's disease on sexual function and psychological status of male patients. *J Sex Med*. 2011; 8:1426–33. [PubMed: 20946153]
236. Kocak M, Basar MM, Vahapoglu G, Mert HC, Gungor S. The effect of Behcet's disease on sexual function and psychiatric status of premenopausal women. *J Sex Med*. 2009; 6:1341–8. [PubMed: 19040624]
237. Pincus T, Sokka T. Can a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores be informative in patients with all rheumatic diseases? *Best Pract Res Clin Rheumatol*. 2007; 21:733–53. [PubMed: 17678833]

238. Taner E, Cosar B, Burhanoglu S, Calikoglu E, Onder M, Arikan Z. Depression and anxiety in patients with Behcet's disease compared with that in patients with psoriasis. *Int J Dermatol*. 2007; 46:1118–24. [PubMed: 17988328]
239. Tanriverdi N, Taskintuna, Duru C, Ozdal P, Ortac S, Firat E. Health-related quality of life in Behcet patients with ocular involvement. *Jpn J Ophthalmol*. 2003; 47:85–92. [PubMed: 12586184]
240. Uguz F, Dursun R, Kaya N, Cilli AS. Quality of life in patients with Behcet's disease: the impact of major depression. *Gen Hosp Psychiatry*. 2007; 29:21–4. [PubMed: 17189740]
241. Karlidag R, Unal S, Evereklioglu C, Sipahi B, Er H, Yologlu S. Stressful life events, anxiety, depression and coping mechanisms in patients with Behcet's disease. *J Eur Acad Dermatol Venereol*. 2003; 17:670–5. [PubMed: 14761134]
242. Sut N, Seyahi E, Yurdakul S, Senocak M, Yazici H. A cost analysis of Behcet's syndrome in Turkey. *Rheumatology*. 2007; 46:678–82. [PubMed: 17121761]
243. Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behcet disease: a randomized, placebo-controlled, double-blind study. *Arch Dermatol*. 1999; 135:529–32. [PubMed: 10328192]
244. Avci O, Gurler N, Gunes AT. Efficacy of cyclosporine on mucocutaneous manifestations of Behcet's disease. *J Am Acad Dermatol*. 1997; 36(Pt 1):796–7. [PubMed: 9146551]
245. Kaneko F, Oyama N, Nishibu A. Streptococcal infection in the pathogenesis of Behcet's disease and clinical effects of minocycline on the disease symptoms. *Yonsei Med J*. 1997; 38:444–54. [PubMed: 9509915]
246. Davies UM, Palmer RG, Denman AM. Treatment with acyclovir does not affect orogenital ulcers in Behcet's syndrome: a randomized double-blind trial. *Br J Rheumatol*. 1988; 27:300–2. [PubMed: 3044474]
247. Hamuryudan V, Yurdakul S, Rosenkaimer F, Yazici H. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behcet's syndrome: a randomized, double blind trial. *Br J Rheumatol*. 1991; 30:395–6. [PubMed: 1913022]
248. Tasli L, Mat C, De Simone C, Yazici H. Lactobacilli lozenges in the management of oral ulcers of Behcet's syndrome. *Clin Exp Rheumatol*. 2006; 5(Suppl 42):S83–6. [PubMed: 17067433]
249. Ergun T, Gurbuz O, Yurdakul S, Hamuryudan V, Bekiroglu N, Yazici H. Topical cyclosporine-A for treatment of oral ulcers of Behcet's syndrome. *Int J Dermatol*. 1997; 36:720. [PubMed: 9352422]
250. Hamza MH. Treatment of Behcet's disease with thalidomide. *Clin Rheumatol*. 1986; 5:365–71. [PubMed: 3780143]
251. Boyvat A, Sisman-Solak C, Gurler A. Long-term effects of interferon alpha 2A treatment in Behcet's disease. *Dermatology*. 2000; 201:40–3. [PubMed: 10971058]
252. Martenet AC, Paccolat F. Traitement immunosuppresseur du syndrome de Behçet. Les résultats à long terme [French]. Immunosuppressive treatment of Behcet's syndrome. Long-term results. *Ophtalmologie*. 1989; 3:40–2. [PubMed: 2641069]
253. Zaghetto JM, Yamamoto MM, Souza MB, Silva FT, Hirata CE, Olivalves E, et al. Chlorambucil and cyclosporine A in Brazilian patients with Behcet's disease uveitis: a retrospective study. *Arq Bras Oftalmol*. 2010; 73:40–6. [PubMed: 20464112]
254. Kim WU, Chung SM, Han TW, Sah WJ, Kim MH. Elevated soluble Fas in aqueous humor of patients with Behcet's uveitis: correlation with uveitis severity. *Jpn J Ophthalmol*. 2002; 46:18–23. [PubMed: 11853709]
255. Blackford S, Finlay AY, Roberts DL. Quality of life in Behcet's syndrome: 335 patients surveyed. *Br J Dermatol*. 1997; 136:293. [PubMed: 9068759]
256. Moses Alder N, Fisher M, Yazici Y. Behcet's syndrome patients have high levels of functional disability, fatigue and pain as measured by a Multi-dimensional Health Assessment Questionnaire (MDHAQ). *Clin Exp Rheumatol*. 2008; 26(Suppl 50):S110–3. [PubMed: 19026127]

Figure 1.
Outcomes and outcome measures used in studies of Behçet syndrome: systematic literature search strategy and results.

Table 1

Overall disease assessment outcomes and outcome measures used in studies of Behçet syndrome. Numerals in parentheses indicate references.

	RCT [*] , n = 25	Other ^{**} , n = 150	Biomarker, n = 73	Overall, n = 248
Behçet's Disease Current Activity Form (BDCAF) (7-30)	–	17	7	24
Clinical Disease Activity Index (32)	–	1	–	1
Clinical Manifestations Index (33,34,35)	1	2	–	3
Iranian BD Dynamic Activity Measure (18,20,31,37)	1	3	–	4
1994 Criteria for Disease Activity of BD (36)	–	1	–	1
Activity, self-defined (38-87)	–	4	46	50
Activity, not defined (88-91)	–	–	4	4
Krause's total severity score (38,46,51,57,104-114)	–	11	4	15
Severity (self-defined) (12,32,60,65,82,115-117)	1	2	6	9
Relapse (30,119-121)	–	2	1	3
Response (complete/partial) (30,122,123)	–	3	–	3
Remission (complete/partial) (71,72,90,119-121)	1	1	4	6
Physicians Global Assessment (18,211)	–	2	–	2
BD Quality of Life (19,124,125)	–	3	–	3
Proportion of patients remaining on treatment (30)	–	1	–	1
Development of major organ involvement (98,122,174)	1	2	–	3
Death (92-103)	–	11	–	11

* Only 4 of the 25 RCT used an outcome measure for overall disease assessment.

** The outcome measures used in uncontrolled interventional studies, cohorts, and case control studies are given together under the "other studies" column. A total of 66 outcome measures for overall disease assessment were used in these 150 studies. Similarly, biomarker studies and generic association studies are given together under the "Biomarker" column. RCT: randomized controlled trial; BD: Behçet disease.

Table 2

Organ specific outcomes and outcome measures used in studies of Behçet syndrome for mucocutaneous, musculoskeletal, eye, vascular, neurologic, and gastrointestinal involvement. Numerals in parentheses indicate references.

	RCT	Other [*]	Biomarker	Overall
Mucocutaneous disease (n)	18	14	0	32
Frequency of oral ulcers/genital ulcers/nodular lesions/papulopustular lesions (57,120,131,135,138,139,243,245)	6	2	–	8
Number of oral ulcers/genital ulcers/nodular lesions/papulopustular lesions (127,128,130,132-135,137,139,140,185,244,246-248)	10	5	–	15
Duration of oral ulcers/genital ulcers/nodular lesions/papulopustular lesions (118,120,135,138)	3	1	–	4
Size of oral ulcers/genital ulcers (129,130,135,244,249)	3	2	–	5
Pain of oral ulcers/genital ulcers (120,129-131,134,243)	4	2	–	6
Severity of oral ulcers/genital ulcers (118,246)	1	1	–	2
Healing time of oral ulcers/genital ulcers (57,128-131,243,249)	2	5	–	7
Depth of oral ulcers/genital ulcers (244)		1	–	1
Pathergy positivity (35,133,244)	1	2	–	3
Oral Ulcer Activity Index (126)		1	–	1
Response (complete/partial) (30,118,136,137,250)	3	2	–	5
Remission (complete/partial) (251)	–	1	–	1
Musculoskeletal disease (n)	6	1	–	7
No. arthritis episodes (132,133,137,139,142)	5		–	5
Frequency of arthritis episodes (139,141)	1	1	–	2
Severity of arthritis episodes (142)	1	–	–	1
Duration of arthritis episodes (139,142,143)	3	–	–	3
Tender joint score (143)	1	–	–	1
Degree of joint swelling (143)	1	–	–	1
Arthritis pain visual analog scale (143)	1	–	–	1
Vascular (n)	–	14	–	14
Venous thrombosis relapse (92,95,197)	–	3	–	3
New/recurrent aneurysm (96,100,198,199,201,203)	–	6	–	6
Disappearance of intracardiac thrombus (202)	–	1	–	1
Remission (93,94)	–	2	–	2
Death (92-96,100,102,199)	–	8	–	8
Amputation (96)	–	1	–	1
Operation need (95)	–	1	–	1
Postoperative complications (96,100,199,200,203)	–	5	–	5
Graft occlusion/patency (96,100,199,200,201,203)	–	6	–	6
Neurologic (n)	–	7	–	8
Functional outcome (independent/dependent/death) (206,210)	–	2	–	2
Improvement (97,204)	–	2	–	2
Poor outcome (97)	–	1	–	1
Death (97)	–	1	–	1

	RCT	Other [*]	Biomarker	Overall
Relapse (204,205)	–	2	–	2
Progressive course (205)	–	1	–	1
Expanded Disability Status Scale (205,208,209)	–	3	–	3
Neuropathic pain (207)	–	1	–	1
Multiple sclerosis functional compound scale (208)	–	1	–	1
Eye involvement (n)	7	53	3	63
Ocular inflammatory attack (9,15,120,144,147,155-158,161,162,164-166,169-171,173,176,181,183,184,186,188-196)	6	25	1	32
Visual acuity (9,15,16,120,144-190)	7	43	1	51
Loss of useful vision/blindness (99,160,163,167,174-177)	–	8	–	8
Improvement of uveoretinitis (145)	–	1	–	1
Retinal vasculitis (149,166,181,185)	2	1	1	4
Hypopyon (149,166,181,185)	2	1	1	4
Ben Ezra Disease Activity Index (15,25,152,153)	1	3	–	4
Total Inflammatory Activity Index (152,153)	–	2	–	2
Total Adjusted Disease Act Index (152,153)	–	2	–	2
Worsening of intraocular inflammation (190)	1	–	–	1
Regression of inflammatory signs (252)	–	1	–	1
Improvement in fundus fluorescein angiography findings (168)	1	–	–	1
Macular thickness (146,181)	1	1	–	2
Remission (16,155,157,163,165,169,186,193)	–	7	1	8
Response (complete/partial) (155,161)	–	2	–	2
Time to remission (191)	–	1	–	1
Time to relapse/recurrence (15,191,194)	–	3	–	3
National Eye Institute Visual Functioning Questionnaire (151)	–	1	–	1
Number of relapse-free patients (147)	–	1	–	1
Inflammation score – self-defined (159)	–	1	–	1
Duration of ocular attacks (171,188)	–	2	–	2
Vascular sheathing (181)	–	1	–	1
Venous occlusion (181)	–	1	–	1
Vitreous condensation (181)	–	1	–	1
SUN visual loss (16)	–	1	–	1
SUN lowering glucocorticoid dose to < 10 mg/day (253)	–	1	–	1
SUN control of uveitis with quiescence during maintenance (150)	–	1	–	1
SUN ocular relapse per patient year (150)	–	1	–	1
SUN intraocular inflammation (146,154,176)	–	3	–	3
SUN level of steroid dependence (154)	–	1	–	1
SUN complete/partial/no response (154)	–	1	–	1
SUN improvement/worsening (15,176)	–	2	–	2
Hogan's ocular inflammatory attack criteria for anterior uveitis (180,188,254)	–	3	–	3
Kimura's ocular inflammatory attack criteria for posterior uveitis (180,188)	–	2	–	2
Development of new eye disease (174,185)	1	1	–	2

	RCT	Other [*]	Biomarker	Overall
Gastrointestinal (n)	–	14	3	17
Disease Activity Index for Intestinal BD (211,216,218,220,221)	–	4	1	5
Inflammatory Bowel Disease Questionnaire (224)	–	1	–	1
Crohn's Disease Activity Index (211,224,227)	–	3	–	3
Harvey Bradshaw Index for Activity (224,227)	–	2	–	2
St. Mark's Activity Index (224)	–	1	–	1
Relapse/recurrence (212-215,217,219,222,223,225,226)	–	9	1	10
Remission (212-214,223)	–	3	1	4
Operation need (211,212,214,217,221,223)	–	5	1	6
Reoperation need (213,217,219,222,225,226)	–	6		6
Physician's global assessment (211)	–	1		1
Immunosuppressive need (217,221)	–	2		2
Glucocorticoid requirement (217,221)	–	2		2

^{*} The outcome measures used in uncontrolled interventional studies, cohorts, and case control studies are given together under the "Other Studies" column. Similarly, biomarker studies and genetic association studies are given together under the "Biomarker" column. RCT: randomized controlled trial; BD: Behçet disease; SUN: Standardization of Uveitis Nomenclature.

Table 3

Nondisease-specific outcome measures used in studies of Behçet syndrome. Numerals in parentheses indicate references.

	RCT, n = 0	Other, n = 36	Biomarker, n = 0	Overall, n = 36
SF-36 (46,57,151,239)	–	4	–	4
Health-related QOL (224,239)	–	2	–	2
WHO QOL 100 (46)	–	1	–	1
WHO QOL BREF (240)	–	1	–	1
EQ-5D (229)	–	1	–	1
Dermatology Life Quality Index (12,255)	–	2	–	2
Oral Health Related Quality of Life (57)	–	1	–	1
Oral Health Impact Profile (57,128,131,234)	–	4	–	4
Nottingham Health Profile (23,141)	–	2	–	2
Life Satisfaction Index (23)	–	1	–	1
Lawton Instrumental Activities of Daily Living (125)	–	1	–	1
Kate Index of Activities of Daily Living (125)	–	1	–	1
Health Assessment Questionnaire (HAQ) (124,141)	–	2	–	2
Multidimensional HAQ (MDHAQ) (237,256)	–	2	–	2
Brief Symptom Inventory (230)	–	1	–	1
Beck Depression Scale (17,60,141,208,230,232,235,236,238,239,240)	–	11	–	11
Beck Anxiety Scale (230,238,239,241)	–	4	–	4
Beck Hopelessness Scale (238)	–	1	–	1
Hamilton Depression Rating Scale (12,228,241)	–	3	–	3
Hamilton Anxiety Rating Scale (12,228)	–	2	–	2
Center for Epidemiologic Studies Depression Scale (19)	–	1	–	1
Psychological General Wellbeing Scale (124,207)	–	2	–	2
Automatic Thoughts Questionnaire (238)	–	1	–	1
Hospital Depression Scale (231)	–	1	–	1
Hospital Anxiety Scale (231)	–	1	–	1
State Trait Anxiety Inventory (60,141)	–	2	–	2
Toronto Alexithymia Scale (241)	–	1	–	1
Epworth Sleepiness Scale (12)	–	1	–	1
Respiratory Disturbance Index (12)	–	1	–	1
Apneahypopnea Index (12)	–	1	–	1
Pittsburgh Sleep Quality Index (12,207)	–	2	–	2
Female Sexual Function Index (236)	–	1	–	1
International Index of Erectile Function (235)	–	1	–	1
Arizona Sexual Experience Scale (228)	–	1	–	1
Golombok Rust Sexual Satisfaction Scale (228)	–	1	–	1
Voice Handicap Test (233)	–	1	–	1
Fibromyalgia Impact Questionnaire (10,60)	–	2	–	2
Fatigue Severity Scale (12)	–	1	–	1

SF-36: Medical Outcomes Study Short Form-36; WHO: World Health Organization; QOL: quality of life.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript